- Trials with a EudraCT protocol (552)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
552 result(s) found for: Experimental drug.
Displaying page 5 of 28.
EudraCT Number: 2012-003738-18 | Sponsor Protocol Number: M13-862 | Start Date*: 2013-04-26 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A Randomized, Open-Labeled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 and ABT-333 Co-administered with Ribavirin Compared to Telaprevir Co-administered with Pegylated In... | |||||||||||||
Medical condition: Chronic Hepatitis C Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) FI (Completed) SK (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-010288-17 | Sponsor Protocol Number: 1516 | Start Date*: 2009-07-13 |
Sponsor Name:Karolinska Hospital | ||
Full Title: Breast cell turnover and mammographic density in women with Polycystic Ovary Syndrome (PCOS) | ||
Medical condition: Polycystic ovary syndrome (PCOS) is the most common hormonal aberration in women of fertile age, with a prevalence of 5-10%, and is associated with chronic anovulation, hyperandrogenism and PCO mo... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-005504-34 | Sponsor Protocol Number: C-II-010 | Start Date*: 2014-07-11 |
Sponsor Name:CESAR Central European Society for Anticancer Drug Research - EWIV | ||
Full Title: Randomized phase II CAbazitaxel dose Individualization and Neutropenia prevention TriAl (CAINTA) | ||
Medical condition: Stage II with advanced Castration-Resistant Prostate Cancer (CRPC) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: AT (Completed) DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-000290-23 | Sponsor Protocol Number: HULPVAS-2011-01 | Start Date*: 2013-02-06 |
Sponsor Name:Fundación para la Investigación Biomédica del Hospital Universitario La Paz | ||
Full Title: Clinical trial phase IIa to safety treating critical ischemia non-revascularizable lower limb by mesenchymal stem cells. | ||
Medical condition: Treatment of critical limb ischemia non-revascularization by mesenchymal stem cells. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-004435-30 | Sponsor Protocol Number: SC06-02 | Start Date*: 2006-10-31 | |||||||||||
Sponsor Name:FONDAZIONE SANTA LUCIA | |||||||||||||
Full Title: Protocol of study for the evaluation of the efficacy of rivastigmine on cognitive and behavioural disorders, following traumatic brain injury TBI in chronic patients. | |||||||||||||
Medical condition: Patients with cognitive and behavioural disorders following severe TBI and other severe acquired brain injury Glasgow Coma Scale GCS lower or equal 8 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001532-11 | Sponsor Protocol Number: 01apr2014 | Start Date*: 2014-09-11 |
Sponsor Name:Ospedale San Raffaele | ||
Full Title: MONO-INSTITUTIONAL PHASE II TRIAL ADDRESSING TOLERABILITY AND ACTIVITY OF R-CHOP CHEMOIMMUNOTHERAPY PRECEDED BY BLOOD-BRAIN BARRIER PERMEABILIZATION BY NGR-TUMOR NECROSIS FACTOR IN PATIENTS WITH RE... | ||
Medical condition: Primary non-Hodgkin lymphoma in the central nervous system relapse / refractory | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-005521-12 | Sponsor Protocol Number: OX-NAL14 | Start Date*: 2015-10-26 | |||||||||||
Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO | |||||||||||||
Full Title: MANAGMENT OF PATIENT WITH MODERATE TO SEVERE POSTOPERATIVE PAIN AFTER SURGERY FOR HYSTERECTOMY: BLIND, RANDOMZATED, CONTROLLATED EXPERIMENTAL STUDY ON THE CONTROL OF PAIN SYNTOMS AND SIDE EFFECTS T... | |||||||||||||
Medical condition: POSTOPERATIVE PAIN AFTER HYSTERECTOMY | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003063-26 | Sponsor Protocol Number: 1634 | Start Date*: 2023-08-10 | |||||||||||
Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC) | |||||||||||||
Full Title: Personalized Risk-Adapted Therapy in Post-Pubertal Patients with Newly Diagnosed Medulloblastoma (PersoMed-I) | |||||||||||||
Medical condition: Newly Diagnosed Medulloblastoma | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) DE (Trial now transitioned) IT (Prematurely Ended) FR (Prematurely Ended) NL (Completed) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-002066-35 | Sponsor Protocol Number: A3921035 | Start Date*: 2008-03-28 | |||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED ACTIVE COMPARATOR, MULTICENTER STUDY TO COMPARE 5 DOSE REGIMENS OF CP-690,550 AND ADALIMUMAB VERSUS PLACEBO, ADMINISTERED FOR 6 MONTHS IN TH... | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) IT (Completed) GR (Completed) CZ (Completed) BG (Completed) SK (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003735-16 | Sponsor Protocol Number: KILT | Start Date*: 2021-06-16 | ||||||||||||||||
Sponsor Name:LYSARC | ||||||||||||||||||
Full Title: A RANDOMIZED NON COMPARATIVE PHASE II STUDY OF LACUTAMAB WITH GEMOX VERSUS GEMOX ALONE IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA | ||||||||||||||||||
Medical condition: Relapsed/refractory PTCL KIR3DL2-positive patients after at least one previous line of systemic based regimen of chemotherapy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005522-29 | Sponsor Protocol Number: M14-002 | Start Date*: 2013-04-17 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in ... | |||||||||||||
Medical condition: Chronic Hepatitis C Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002380-26 | Sponsor Protocol Number: Somagel | Start Date*: 2018-09-13 | |||||||||||
Sponsor Name:SOCIETÀ ITALO BRITANNICA L. MANETTI - H. ROBERTS & C. PER AZIONI | |||||||||||||
Full Title: Single-group, open study on the systemic bioavailability, safety and local tolerability of a new gel formulation of Somatoline¿ in 30 healthy women. | |||||||||||||
Medical condition: Edematous fibrosclerotic panniculopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001953-18 | Sponsor Protocol Number: M14-490 | Start Date*: 2014-10-13 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: An Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Ombitasvir/ ABT-450/ Ritonavir and Dasabuvir in Adults with Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosi... | |||||||||||||
Medical condition: Chronic Hepatitis C infection and compensated cirrhosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004997-24 | Sponsor Protocol Number: AT-01C-001 | Start Date*: 2020-03-11 | |||||||||||
Sponsor Name:Atea Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase I/IIa Study Assessing AT-777 in Healthy Subjects and AT-777 in Combination with AT-527 in HCV-Infected Subjects | |||||||||||||
Medical condition: HCV-Infected subjects | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001363-12 | Sponsor Protocol Number: TRIANGLE | Start Date*: 2016-03-24 | |||||||||||||||||||||
Sponsor Name:Klinikum der Universität München, Medizinische Klinik und Poliklinik III | |||||||||||||||||||||||
Full Title: autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized European MCL Network trial | |||||||||||||||||||||||
Medical condition: Generalized mantle cell Lymphoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Trial now transitioned) SE (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) FI (Trial now transitioned) CZ (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned) HR (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-005036-24 | Sponsor Protocol Number: A3921025 | Start Date*: 2007-05-04 | |||||||||||
Sponsor Name:Pfizer Ltd - Ramsgate Road, Sandwich CT139NJ, UK. | |||||||||||||
Full Title: A PHASE 2B, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY TO COMPARE 6 DOSE REGIMENS OF CP 690,550 VS. PLACEBO, EACH COMBINED WITH METHOTREXATE, ADMINISTERED FOR 6 MONTHS IN THE T... | |||||||||||||
Medical condition: Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) SK (Completed) CZ (Completed) HU (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002035-29 | Sponsor Protocol Number: M13-098 | Start Date*: 2013-01-24 | |||||||||||
Sponsor Name:Abbott GmbH & Co. KG | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co administered with Ribavirin (RBV) in Treat... | |||||||||||||
Medical condition: Chronic Hepatitis C Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) CZ (Completed) PT (Completed) IE (Completed) NL (Completed) IT (Completed) DK (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-018313-29 | Sponsor Protocol Number: PPA/904A/001 | Start Date*: 2010-03-23 | |||||||||||
Sponsor Name:Photopharmica | |||||||||||||
Full Title: Open-label, within-subject controlled, Phase IIa study to investigate repeat dose antimicrobial photodynamic therapy in patients with acne vulgaris. | |||||||||||||
Medical condition: Acne vulgaris | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000044-18 | Sponsor Protocol Number: GEM2017FIT | Start Date*: 2018-07-04 | |||||||||||
Sponsor Name:Fundación PETHEMA | |||||||||||||
Full Title: Induction therapy with bortezomib-melphalan and prednisone (VMP) followed by lenalidomide and dexamethasone (Rd) versus carfilzomib, lenalidomide and dexamethasone (KRd) plus/minus daratumumab, 18 ... | |||||||||||||
Medical condition: Multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-004840-30 | Sponsor Protocol Number: TREAT | Start Date*: 2006-07-26 | |||||||||||
Sponsor Name:Thoraxklinik Heidelberg | |||||||||||||
Full Title: ADJUVANT CHEMOTHERAPY WITH PEMETREXED AND CISPLATIN vs. VINORELBINE AND CISPLATIN IN NSCLC IB, IIA, IIB, T3N1: A RANDOMIZED PHASE II STUDY | |||||||||||||
Medical condition: Patients with pathologically confirmed, R0 resected non-small cell lung cancer (NSCLC), pathologic stage IB, IIA, IIB, T3N1 (without need for further radiotherapy); systematic lymph node dissection... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
